Literature DB >> 18682567

Morphine tolerance in the mouse ileum and colon.

Gracious R Ross1, Bichoy H Gabra, William L Dewey, Hamid I Akbarali.   

Abstract

Repeated administration of morphine is associated with tolerance to its antinociceptive properties. However, constipation remains the major side effect of chronic exposure to morphine. In contrast, previous studies suggest that tolerance to opioids develops in the ileum of several species. In this study, we provide evidence that constipation may arise due to a lack of tolerance development to morphine in the colon. Mice received implants with either placebo or 75 mg of morphine pellets, and they were examined for morphine tolerance to antinociception, defecation, and intestinal and colonic transit after 72 h. Tissues were obtained from the ileum and distal colon, and contractile responses were measured from longitudinal and circular muscle preparations. In morphine-pelleted mice, a 5.5-fold tolerance developed to antinociception after 72 h, and a 53.2-fold tolerance developed in mice that received an additional daily morphine injection. In both models, intestinal transit but not defecation or colonic transit developed tolerance. In isolated longitudinal muscles, electrical field stimulation-induced cholinergic contractions were dose-dependently inhibited by morphine in both the ileum and colon of placebo pelleted with a pD(2) of 7.1 +/- 0.4 and 7.8 +/- 0.4, respectively. However, the dose response to morphine inhibition was shifted to the right for the ileum from morphine-pelleted mice (pD(2) = 5.1 +/- 0.4) but not the colon (pD(2) = 6.9 +/- 0.4). In circular muscle preparations, morphine induced atropine-insensitive contractions in both tissue segments. Tolerance to morphine developed in the ileum but not the colon upon repeated administration of morphine. These findings indicate that a lack of tolerance development in the colon is the basis for opioid bowel dysfunction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18682567      PMCID: PMC2574683          DOI: 10.1124/jpet.108.143438

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  33 in total

Review 1.  Cellular and synaptic adaptations mediating opioid dependence.

Authors:  J T Williams; M J Christie; O Manzoni
Journal:  Physiol Rev       Date:  2001-01       Impact factor: 37.312

2.  The importance of opioid tolerance: a therapeutic paradox.

Authors:  A Reed Thompson; James B Ray
Journal:  J Am Coll Surg       Date:  2003-02       Impact factor: 6.113

3.  The expression of a high level of morphine antinociceptive tolerance in mice involves both PKC and PKA.

Authors:  Forrest L Smith; Ruby R Javed; Mark J Elzey; William L Dewey
Journal:  Brain Res       Date:  2003-09-19       Impact factor: 3.252

4.  Gut motility and transit changes in patients receiving long-term methadone maintenance.

Authors:  C S Yuan; J F Foss; M O'Connor; J Moss; M F Roizen
Journal:  J Clin Pharmacol       Date:  1998-10       Impact factor: 3.126

5.  Specific opiate receptors on isolated mammalian gastric smooth muscle cells.

Authors:  K N Bitar; G M Makhlouf
Journal:  Nature       Date:  1982-05-06       Impact factor: 49.962

6.  Identification of opioid receptors on gastric muscle cells by selective receptor protection.

Authors:  J R Grider; G M Makhlouf
Journal:  Am J Physiol       Date:  1991-01

7.  A rapid and simple method for the quantitative determination of tolerance development to opiates in the guinea-pig ileum in vitro.

Authors:  A Rezvani; J P Huidobro-Toro; J Hu; E L Way
Journal:  J Pharmacol Exp Ther       Date:  1983-05       Impact factor: 4.030

8.  Involvement of phospholipid signal transduction pathways in morphine tolerance in mice.

Authors:  F L Smith; A B Lohmann; W L Dewey
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

9.  Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model.

Authors:  G S Ling; D Paul; R Simantov; G W Pasternak
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

10.  Suppression of inhibitory neural input to colonic circular muscle by opioid peptides.

Authors:  J R Grider; G M Makhlouf
Journal:  J Pharmacol Exp Ther       Date:  1987-10       Impact factor: 4.030

View more
  43 in total

1.  Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents.

Authors:  Ahmad A Altarifi; Bethany David; Karan H Muchhala; Bruce E Blough; Hamid Akbarali; S Stevens Negus
Journal:  J Psychopharmacol       Date:  2017-02-01       Impact factor: 4.153

Review 2.  Site and mechanism of morphine tolerance in the gastrointestinal tract.

Authors:  H I Akbarali; A Inkisar; W L Dewey
Journal:  Neurogastroenterol Motil       Date:  2014-10       Impact factor: 3.598

3.  CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward.

Authors:  Maciej Gonek; Virginia D McLane; David L Stevens; Kumiko Lippold; Hamid I Akbarali; Pamela E Knapp; William L Dewey; Kurt F Hauser; Jason J Paris
Journal:  Brain Behav Immun       Date:  2017-11-13       Impact factor: 7.217

4.  Connexin-purinergic signaling in enteric glia mediates the prolonged effect of morphine on constipation.

Authors:  Sukhada Bhave; Aravind Gade; Minho Kang; Kurt F Hauser; William L Dewey; Hamid I Akbarali
Journal:  FASEB J       Date:  2017-03-09       Impact factor: 5.191

5.  The role of β-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea pig gastrointestinal tract.

Authors:  Minho Kang; Hercules T Maguma; Tricia H Smith; Gracious R Ross; William L Dewey; Hamid I Akbarali
Journal:  J Pharmacol Exp Ther       Date:  2011-11-30       Impact factor: 4.030

6.  Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice.

Authors:  Divya Ramesh; Gracious R Ross; Joel E Schlosburg; Robert A Owens; Rehab A Abdullah; Steven G Kinsey; Jonathan Z Long; Daniel K Nomura; Laura J Sim-Selley; Benjamin F Cravatt; Hamid I Akbarali; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2011-06-30       Impact factor: 4.030

7.  6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists.

Authors:  Yunyun Yuan; David L Stevens; Amanda Braithwaite; Krista L Scoggins; Edward J Bilsky; Hamid I Akbarali; William L Dewey; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2012-05-26       Impact factor: 2.823

Review 8.  Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities.

Authors:  Alfred D Nelson; Michael Camilleri
Journal:  Therap Adv Gastroenterol       Date:  2015-07       Impact factor: 4.409

9.  Differential tolerance to morphine antinociception in assays of pain-stimulated vs. pain-depressed behavior in rats.

Authors:  Ahmad A Altarifi; S Stevens Negus
Journal:  Eur J Pharmacol       Date:  2014-12-18       Impact factor: 4.432

10.  Enhanced Sensitivity of α3β4 Nicotinic Receptors in Enteric Neurons after Long-Term Morphine: Implication for Opioid-Induced Constipation.

Authors:  Aravind R Gade; Minho Kang; Fayez Khan; John R Grider; M Imad Damaj; William L Dewey; Hamid I Akbarali
Journal:  J Pharmacol Exp Ther       Date:  2016-04-11       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.